source
- Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular target…
- Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancerDr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer. She notes that, as of 2026, ther…